SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron is caught in a broader AI-chip selloff as traders worry that calls for tighter AI regulation could slow data-center expansion and weaken future memory demand; community discussion also points to a reported Taiwan plant work stoppage tied to a labor dispute. Bulls view the drop as an overreaction given strong AI-memory demand, while bears warn that spending or memory pricing could peak.

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidia is under pressure amid a broader AI-chip selloff, as traders worry that tighter AI rules and data-center permitting hurdles could slow infrastructure spending; concerns about debt and circular financing in the AI buildout add to doubts about demand sustainability. The community is divided between dip buyers who expect AI demand to persist or shift elsewhere and bears who see a possible capex-driven bubble.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavaxs Q3 update and sharply higher 2026 revenue outlook, supported by a milestone from Sanofis Phase 3 flu-COVID combination trial, are driving attention. Traders welcomed the improved outlook and leaner operations, while skeptics said revenue remains heavily dependent on Sanofi and wanted new partnerships or concrete oncology and MTA updates.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Concerns that Democratic control could bring tighter AI and data-center rules and slow future buildouts have pressured SNDK alongside other memory and semiconductor stocks. Traders are split between viewing the selloff as an overreaction given earnings and memory demand, and worrying about weaker AI infrastructure spending, cyclical pricing pressure, and further downside.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention amid a sharp semiconductor selloff, with traders pointing to fears that Democratic control could constrain AI and data-center expansion, alongside weak reactions to chip-sector reports and concerns about an AI bubble. The community is split between expecting further losses and viewing the heavy selling as capitulation and a dip-buying opportunity.

Snap, Inc. is a technology company, which engages in the provision of a visual messaging application that was created to help people communicate through short videos and images. The company was founded by Frank Reginald Brown IV, Evan Thomas Spiegel, and Robert C. Murphy in 2010 and is headquartered in Santa Monica, CA.

Snap Inc - Ordinary Shares - Class A

Snap Inc

Snaps quarterly report missed revenue and daily-active-user expectations, with sluggish advertising growth weighing on shares despite improved profitability and a stronger outlook. Traders are split between optimism about cash flow and subscriptions and concerns that weak user and ad trendsand the planned shift from DAU to MAU reportingobscure the core businesss momentum.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins record third-quarter results, stronger-than-expected outlook, and expanded buyback are driving attention, with traders crediting improvements in its AI-powered advertising business for the strong report. Bulls are celebrating the sharp rally, while others warn that growth may moderate and the gains could fade.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

CELH is drawing attention after Q3 results beat expectations, led by strong Alani Nu growth and international sales. Traders are weighing that strength against declining revenue for the core Celsius brand and sharply lower gross margins, leaving debate over whether the beat can sustain a recovery.

QUALCOMM, Inc. engages in developing and commercializing foundational technologies and products used in mobile devices and other wireless products. It operates through the following segments: Qualcomm CDMA Technologies (QCT), Qualcomm Technology Licensing (QTL), and Qualcomm Strategic Initiatives (QSI). The QCT segment develops and supplies integrated circuits and system software based on technologies for use in voice and data communications, networking, application processing, multimedia, and global positioning system products. The QTL segment grants licenses and provides rights to use portions of the firm's intellectual property portfolio. The QSI segment focuses on opening new or expanding opportunities for its technologies and supporting the design and introduction of new products and services for voice and data communications. The company was founded by Franklin P. Antonio, Adelia A. Coffman, Andrew Cohen, Klein Gilhousen, Irwin Mark Jacobs, Andrew J. Viterbi, and Harvey P. White in July 1985 and is headquartered in San Diego, CA.

Qualcomm, Inc.

Qualcomms earnings report beat modestly, but a sharp decline in handset revenue and margin pressure from rising component costs overshadowed the results and cautious earnings outlook, prompting a steep post-report selloff. Traders are debating whether growth in automotive, data center and other non-handset businesses can offset the weakness in its smartphone business.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arms quarterly results beat headline expectations, but softer royalty revenue and a largely in-line outlook have overshadowed strong licensing growth and weighed on the shares. Traders are split between buying the dip on AI and data-center demand and questioning whether recurring royalty growth and the companys valuation justify the premium amid weakness in chip stocks.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Deadline Alert: Tenax Therapeutics, Inc. Shareholders Have Until December 28, 2026 to Seek Lead Plaintiff Appointment in Securities Fraud Lawsuit, The Law Offices of Frank R. Cruz Notes

The deadline for Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) investors to seek appointment as lead plaintiff in a securities class action lawsuit is December 28, 2026. The lawsuit was filed on behalf of investors who purchased or otherwise acquired Tenax Therapeutics, Inc...

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 28, 2026 in Tenax Therapeutics, Inc. Lawsuit - TENX

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 28, 2026 in Tenax Therapeutics, Inc. Lawsuit - TENX Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of December 28, 2026 in Tenax Therapeutics, Inc. Lawsuit - TENXPR NewswireNEW YORK, Nov. 4, 2026 Key...

Securities Fraud Class Action Lawsuit Pending Against Tenax Therapeutics, Inc.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline

Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) is the subject of a securities fraud class action lawsuit filed on behalf of investors who purchased or otherwise acquired the Company's securities from November 13, 2023 through August 7, 2026, inclusive. The Law Offices of Howard...

Securities Fraud Class Action Filed Against Tenax Therapeutics, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

A securities fraud class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors who purchased or otherwise acquired the Company's securities between November 13, 2023 and August 7, 2026, inclusive. Glancy Prongay Wolke...

Securities Fraud Lawsuit Filed Against Tenax Therapeutics, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline

A securities class action lawsuit has been filed against Tenax Therapeutics, Inc. ("Tenax" or the "Company") (NASDAQ: TENX) on behalf of investors who purchased or otherwise acquired Tenax Therapeutics, Inc. securities from November 13, 2023 to August 7, 2026, inclusive. The Law Offices of Frank R...

TENX INVESTOR ALERT: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 Deadline

TENX INVESTOR ALERT: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026 Deadline TENX INVESTOR ALERT: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit Before December 28, 2026...

SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) -- Investors Who Suffered Losses Are Encouraged to Contact the Firm.

SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics, Inc. (NASDAQ: TENX) -- Investors Who Suffered Losses Are Encouraged to Contact the Firm. SHAREHOLDER ALERT: Bronstein Gewirtz & Grossman, LLC Announces Class Action Against Tenax Therapeutics...

Lost Money on Tenax Therapeutics, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 89.77% Share Price Drop

Investors who lost money on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover their losses. Glancy Prongay Wolke & Rotter LLP ("Glancy") today announced a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors into whether...

ATTENTION NASDAQ: TENX INVESTORS: Contact Berger Montague About a Tenax Therapeutics, Inc. Class Action Lawsuit

ATTENTION NASDAQ: TENX INVESTORS: Contact Berger Montague About a Tenax Therapeutics, Inc. Class Action Lawsuit ATTENTION NASDAQ: TENX INVESTORS: Contact Berger Montague About a Tenax Therapeutics, Inc. Class Action LawsuitPR NewswirePHILADELPHIA, Oct. 30, 2026 PHILADELPHIA, Oct. 30, 2026...

Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G. Smith Announces Securities Fraud Investigation After 89.77% Share Price Decline

Investors who suffered losses on Tenax Therapeutics, Inc. ("Tenax" or the "Company") stock may have claims to recover those losses. The Law Offices of Howard G. Smith today reported that it is conducting a securities fraud investigation on behalf of Tenax Therapeutics, Inc. (NASDAQ: TENX) investors...

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

Tenax Therapeutics Inc

Why Did TENX Stock Crash 89% Today?

Equity

Extremely Bearish Sentiment

<ul class="summary-bullets"><li>The Phase 3 LEVEL trial enrolled 241 patients and evaluated whether TNX-103 could improve how far patients could walk in six minutes after 12 weeks of treatment.</li><li>Patients receiving TNX-103 improved their six-minute walk distance by 14 meters, compared with 10.4 meters for placebo, which is not considered statistically significant.</li><li>Tenax said it plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the full results and potentially adjust future trials.</li></ul>Shares of Tenax Therapeutics (TENX) crashed nearly 89% to a record low in early trading on Monday, after the biotech firm’s experimental drug TNX-103 failed to meet the main goal of a late-stage study in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction, or PH-HFpEF.PH-HFpEF is a condition in which pressure in the blood vessels of the lungs increases while the heart has difficulty filling properly.<h2 class="st-heading-2">Phase 3 Trial Misses Primary And Secondary Goals</h2>The Phase 3 LEVEL trial enrolled 241 patients and evaluated whether TNX-103, an oral form of Levosimendan, could improve how far patients could walk in six minutes after 12 weeks of treatment.Patients receiving TNX-103 improved their six-minute walk distance by 14 meters, compared with 10.4 meters for placebo. The 3.5-meter difference was not statistically significant, meaning the study did not show convincing evidence that the improvement was caused by the drug.TNX-103 also failed to significantly improve a key questionnaire measuring heart failure symptoms.However, the trial also showed that patients who could initially walk less than 333 meters improved by 26.3 meters compared with placebo.<h2 class="st-heading-2">Why Management Remains Bullish</h2>TNX-103 also produced a 49% greater reduction in NT-proBNP, a biomarker that rises when the heart is under stress, compared with placebo. The drug also reduced right ventricular systolic pressure, a measure of pressure on the right side of the heart, by 3.5 millimeters of mercury compared with placebo. Tenax said TNX-103 was generally well tolerated with no new safety signals.Tenax said it plans to meet with the U.S. Food and Drug Administration (FDA) to discuss the full results and potentially adjust future trials to focus on patients who showed a stronger response to TNX-103. The company will also seek guidance from European regulators.“We believe the data from LEVEL provide new information that will guide us toward approval. Our mission is to bring the first approved therapy to patients with PH-HFpEF,” said Chris Giordano, President and CEO.<h2 class="st-heading-2">TENX Traders Call Selloff An Overreaction&nbsp;</h2>Despite the sharp slump, retail sentiment surrounding <a href="https://stocktwits.com/symbol/TENX">TENX</a> on Stocktwits turned ‘extremely bullish’ from ‘bullish’ over the past 24 hours, amid a 1,350% increase in message volumes.One user called the selloff an “overreaction.”<stembedurl>https://stocktwits.com/MyJesusID/message/661410561</stembedurl>Another user said the reduction in NT-proBNP is potentially “much more interesting” than the walking data.<stembedurl>https://stocktwits.com/majsterJoda/message/661405355</stembedurl>The stock is down 86% so far this year.Also read:<a href="https://stocktwits.com/news-articles/markets/equity/moon-lake-psoriatic-arthritis-drug-shows-promise-in-phase-3-trial/cZojq84RJOK">&nbsp;MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a chart depicting stock market crash, is displayed on a mobile phone screen in Ankara, Turkiye on August 5, 2024. (Photo by Osmancan Gurdogan/Anadolu via Getty Images)

The biotech firm’s experimental drug TNX-103 failed to meet the main goal of a late-stage study in patients with pulmonary hypertension associated with heart failure with preserved ejection fraction.

Current Price	$1.81
Prev Close	$1.84
Open	$1.85
Dividend Yield	0.00%
50-Day Moving Average	$1.83
Beta	0.77
Avg. Volume	2.06M
PE Ratio	-1.23

52-Week High	$19.40
52-Week Low	$1.31
Market Capitalization	$67.74M
EPS (Annual)	-$1.34
Price to Book	0.51
Revenue Per Employee	$0.00

Feed

News

Sentiment

Fundamentals

Info

TENX Fundamentals